ELAN / Elanco Animal Health Incorporated - Arquivamentos da SEC, Relatório Anual, Declaração de Procuração

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 450 Elanco Circle Indianapolis, Indiana 46221 (Address of princ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 21, 2026 Elanco Animal Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 21, 2026 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Comm

Elanco Animal Health Incorporated Amended and Restated 2018 Elanco Stock Plan Performance-Based Award Agreement

Elanco Animal Health Incorporated Amended and Restated 2018 Elanco Stock Plan Performance-Based Award Agreement This Performance-Based Award is granted on , 2026 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Performance-Based Award Agreement (the “Grantee”).

Elanco Animal Health Reports First Quarter 2026 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2026 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target •First Quarter 2026 Financial Results: ◦Revenue of $1,3

The Elanco Corporate Bonus Plan (as amended effective January 1, 2026) TABLE OF CONTENTS

The Elanco Corporate Bonus Plan (as amended effective January 1, 2026) TABLE OF CONTENTS SECTION 1.

Elanco Animal Health Incorporated Amended and Restated 2018 Elanco Stock Plan Restricted Stock Unit Award Agreement

Elanco Animal Health Incorporated Amended and Restated 2018 Elanco Stock Plan Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2026 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”).

Elanco Animal Health Incorporated Amended and Restated 2018 Elanco Stock Plan Nonqualified Stock Option Award Agreement

Elanco Animal Health Incorporated Amended and Restated 2018 Elanco Stock Plan Nonqualified Stock Option Award Agreement This Nonqualified Stock Option is granted on , 2026 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Nonqualified Stock Option Award Agreement (the “Grantee”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Elanco Animal Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (I.R

Elanco Animal Health Incorporated Amended and Restated 2018 Elanco Stock Plan Restricted Stock Unit Award Agreement

Elanco Animal Health Incorporated Amended and Restated 2018 Elanco Stock Plan Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2026 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the ap

noticeofmlingf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini

Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day Outlook

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growt

ELANCO ANIMAL HEALTH, INCORPORATED DIRECTORS’ DEFERRAL SUB-PLAN TO THE AMENDED AND RESTATED 2018 ELANCO STOCK PLAN Effective September 18, 2018 Amended March 31, 2023 and Amended November 20, 2025

Exhibit 10.31 ELANCO ANIMAL HEALTH, INCORPORATED DIRECTORS’ DEFERRAL SUB-PLAN TO THE AMENDED AND RESTATED 2018 ELANCO STOCK PLAN Effective September 18, 2018 Amended March 31, 2023 and Amended November 20, 2025 Preamble The Directors’ Deferral Sub-Plan is a sub-plan of the Stock Plan, and has been established by the Company for the purpose of providing an opportunity for Directors of the Company w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Elanco Animal H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number 001-38661 Elan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employ

SUBSIDIARIES OF THE COMPANY

SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2025, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Dista Products Limited United Kingdom EIO Insurance Company, Inc. Tennessee (United States) Elanco (Shanghai) Animal Health Co., Ltd. China

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026 Elanco Animal He

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

J.P. Morgan Healthcare Conference Jeff Simmons President & CEO January 13, 2026

Exhibit 99.1 J.P. Morgan Healthcare Conference Jeff Simmons President & CEO January 13, 2026 Notices and Disclaimers Forward - Looking Statements . This presentation contains forward - looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year and fourth quarter guida

Elanco Investor Day Defines New Era as Sustainable Growth Company

Exhibit 99.1 Elanco Animal Health 450 Elanco Circle Indianapolis, IN 46221 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 [email protected] Elanco Investor Day Defines New Era as Sustainable Growth Company · Details three-year outlook with annual mid-single digit top-line organic constant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 5, 2025 Elanco Animal H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 5, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

Elanco Animal Health Reports Third Quarter 2025 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2025 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target •Third Quarter 2025 Financial Results: ◦Revenue of $1,1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Hea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 Elanco Animal He

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2025 Elanco Animal H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

AMENDMENT NO. 3 TO CREDIT AGREEMENT

  Exhibit 10.1   Execution Version   AMENDMENT NO. 3 TO CREDIT AGREEMENT   THIS AMENDMENT NO. 3 TO CREDIT AGREEMENT (this “Agreement”), dated as of October 31, 2025, is entered into among ELANCO ANIMAL HEALTH INCORPORATED, a corporation formed under the laws of Indiana (the “U.S. Borrower” or the “Borrower Representative”), ELANCO US INC., a corporation formed under the laws of Delaware (the “Co-B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Elanco Animal Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (

Elanco Animal Health Reports Second Quarter 2025 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2025 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target •Second Quarter 2025 Financial Results: ◦Revenue of $1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health I

First Amendment to Receivables Loan Agreement by and among Elanco Animal Health Incorporated, solely in its role as performance guarantor, Elanco SPEAR LLC, as borrower, Elanco US Inc., as servicer, Coöperatieve Rabobank U.A., New York Branch, as Administrative Agent, and the lenders from time to time party thereto.

Exhibit 10.1 EXECUTION COPY FIRST AMENDMENT TO RECEIVABLES LOAN AGREEMENT This FIRST AMENDMENT TO RECEIVABLES LOAN AGREEMENT, dated as of June 25, 2025 (this “Amendment”), is entered into by and among Elanco Spear LLC, a Delaware limited liability company, as borrower (the “Borrower”), Elanco US Inc. (“Elanco”), a Delaware corporation, as servicer (the “Servicer”), the various lenders and lender a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 25, 2025 Elanco Animal Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 25, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2500 Innovation Way Greenfield, Indiana (Address of principal e

Transition Agreement, dated as of May 21, 2025, between Elanco Animal Health Incorporated and Todd Young.

Exhibit 10.2 May 21, 2025 Todd Young Re:          Transition Agreement Dear Todd, The purpose of this letter (“Transition Agreement”) is to confirm the terms of your transition and separation from employment with Elanco Animal Health Incorporated (the “Company”). Transition Period Your last day of employment with the Company will be August 31, 2025 (your “Separation Date”). Between now and the clo

Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] Media Contact: Colleen Dekker (317) 989-7011 [email protected] Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer GREENFIELD, Ind. (May 28, 2025) Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive

Employment Offer Letter, dated as of May 20, 2025, between Elanco Animal Health Incorporated and Robert VanHimbergen.

Exhibit 10.1 05/20/2025 Robert VanHimbergen 8124 W. Knightsbridge Drive Mequon, Wisconsin 53097 Dear Bob, It is my pleasure to extend to you a formal offer of employment with Elanco US Inc. and to outline the provisions of that offer in detail. The position is Executive Vice President & Chief Financial Officer reporting to Jeff Simmons, President & Chief Executive Officer. This offer includes an o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 21, 2025 Elanco Animal Healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 21, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2025 Elanco Animal Healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (I.R

The Elanco Corporate Bonus Plan (as amended effective January 1, 2025) TABLE OF CONTENTS

The Elanco Corporate Bonus Plan (as amended effective January 1, 2025) TABLE OF CONTENTS SECTION 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health

Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement

4907-1064-5017.1 Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement This Nonqualified Stock Option is granted on , 2025 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Nonqualified Stock Option Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at

Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement

Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2025 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”).

Elanco Animal Health Reports First Quarter 2025 Results Accelerating Debt Paydown in 2025

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2025 Results Accelerating Debt Paydown in 2025 •First Quarter 2025 Financial Results: ◦Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic const

Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement

Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2025 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”).

Elanco Animal Health Incorporated Performance-Based Award Agreement

Elanco Animal Health Incorporated Performance-Based Award Agreement This Performance-Based Award is granted on , 2025 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Performance-Based Award Agreement (the “Grantee”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat

Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] Media Contact: Colleen Dekker (317) 989-7011 [email protected]   Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets GREENFIELD, Ind. (March 17, 2025) Elanco Animal Health Incor

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

ELANCO ANIMAL HEALTH INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT

Exhibit 10.13 ELANCO ANIMAL HEALTH INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award is granted on , 2024 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at https://o

ELANCO ANIMAL HEALTH INCORPORATED NONQUALIFIED STOCK OPTION AWARD AGREEMENT

Exhibit 10.22 ELANCO ANIMAL HEALTH INCORPORATED NONQUALIFIED STOCK OPTION AWARD AGREEMENT This Nonqualified Stock Option is granted on , 2024 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Nonqualified Stock Option Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at htt

SUBSIDIARIES OF THE COMPANY

SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2024, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Dista Products Limited United Kingdom EIO Insurance Company, Inc. Tennessee (United States) Elanco (Shanghai) Animal Health Co., Ltd. China

Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results •Fourth Quarter 2024 Financial Results: ◦Revenue of $1,020 million, decreased 1% on a reported basis and increased 4% on an organic co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission Fil

ELANCO ANIMAL HEALTH INCORPORATED EXECUTIVE DEFERRAL AND STOCK MATCH PLAN

Exhibit 10.12 ELANCO ANIMAL HEALTH INCORPORATED EXECUTIVE DEFERRAL AND STOCK MATCH PLAN Elanco Animal Health Incorporated (the "Company"), hereby amends and restates the Elanco Animal Health Incorporated Executive Deferral Plan, changes the plan name to Elanco Animal Health Incorporated Executive Deferral and Stock Match Plan (the "Plan") and becomes a sub-plan of the Elanco Stock Plan, effective

ELANCO ANIMAL HEALTH INCORPORATED PERFORMANCE-BASED AWARD AGREEMENT

Exhibit 10.24 ELANCO ANIMAL HEALTH INCORPORATED PERFORMANCE-BASED AWARD AGREEMENT This Performance-Based Award is granted on , 2024 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Performance-Based Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at https://onlineservice

The Elanco Corporate Bonus Plan (as amended effective January 1, 2024) SECTION 1. PURPOSE

Exhibit 10.16 The Elanco Corporate Bonus Plan (as amended effective January 1, 2024) SECTION 1. PURPOSE The purpose of The Elanco Corporate Bonus Plan (the “Plan”) is to encourage and promote eligible employees to create and deliver innovative animal health-based solutions that enable Elanco Animal Health Incorporated (the “Company” or “Elanco”) to meet or exceed its business objectives through a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-38661 Elan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employ

ELANCO ANIMAL HEALTH INCORPORATED INSIDER TRADING AND REGULATION FD POLICY

Exhibit 19 ELANCO ANIMAL HEALTH INCORPORATED INSIDER TRADING AND REGULATION FD POLICY Introduction The purpose of this Insider Trading and Regulation FD Policy (this “Policy”) is to help Elanco Animal Health Incorporated and its subsidiaries (the “Company”) comply with U.

ELANCO ANIMAL HEALTH INCORPORATED 2018 ELANCO STOCK PLAN OMNIBUS AMENDMENT TO STOCK OPTION AGREEMENTS

Exhibit 10.25 ELANCO ANIMAL HEALTH INCORPORATED 2018 ELANCO STOCK PLAN OMNIBUS AMENDMENT TO STOCK OPTION AGREEMENTS This Omnibus Amendment, dated as of March 29, 2024, amends the terms and conditions of those certain award agreements governing the terms of stock option awards granted under the 2018 Elanco Stock Plan (the “Plan”), by and between Elanco Animal Health Incorporated (the “Company”) and

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.5 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Elanco Animal Health Incorporated (“Elanco”) has one class of securities, its common stock, no par value, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Description of common stock The following is a summary of Elanco

ELANCO ANIMAL HEALTH INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT

Exhibit 10.23 ELANCO ANIMAL HEALTH INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award is granted on , 2024 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at https://o

EX-99

EX-99 2 exhibit99.txt Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Diversifying Solutions LLC IA Fidelity Institutional Asset Manageme

EX-99

EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Life Limited BlackRock International Limited BlackRock Advisors, LLC Aperio Group, LLC BlackRock (Netherlands) B.V. BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management,

EX-24

EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam

© 2025 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation

Exhibit 99.1 J.P. Morgan Healthcare Conference January 14, 2025 Jeff Simmons President & Chief Executive Officer © 2025 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation, our expected 2024 full year and fou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 Elanco Animal H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

Elanco Strengthens Board of Directors with Addition of Stacey Ma Ma brings deep manufacturing and innovation expertise

Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Elanco Strengthens Board of Directors with Addition of Stacey Ma Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind. (Nove

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 11, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Hea

Elanco Animal Health Reports Third Quarter 2024 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2024 Results •Third Quarter 2024 Financial Results ◦Revenue of $1,030 million, organic constant currency growth of 1% ◦Reported Net Income of $364 million, Adju

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 16, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

Incremental Assumption Agreement dated August 13, 2024 by and among Elanco Animal Health Incorporated, Elanco US Inc., the subsidiary loan parties party thereto, Farm Credit Mid-America, PCA, as incremental term lender, and Goldman Sachs Bank USA, as the term facility agent.

Exhibit 10.1 EXECUTION VERSION INCREMENTAL ASSUMPTION AGREEMENT THIS INCREMENTAL ASSUMPTION AGREEMENT (this “Agreement”) dated and effective as of August 13, 2024 (the “Effective Date”), is among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the “Company”), ELANCO US INC., a Delaware corporation (together with the Company, collectively, the “Borrowers” and each, individually, a “Borro

FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT

Exhibit 2.1 EXECUTION VERSION FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT This FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”), is hereby entered into as of July 1, 2024, by and between Elanco Animal Health, Inc., an Indiana corporation (“Seller” and, together with the Seller Divesting Entities, the “Seller Parties”), and Intervet International B.V., a Dutch private company with lim

Elanco Animal Health Reports Second Quarter 2024 Results Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2024 Results Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture •Second Quarter 2024 Financial Results ◦Revenue of $1,1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Elanco Animal Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health I

Elanco Completes Sale of Aqua Business Transaction concentrates Elanco’s focus on significant value creation opportunities and accelerates deleveraging progress

Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Katy Grissom (317) 273-9248 [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 [email protected] Elanco Completes Sale of Aqua Business Transaction concentrates Elanco’s focus on significant value creation opportunities and accelerates deleveragin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2024 Elanco Animal Healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

ELAN / Elanco Animal Health Incorporated / BlackRock Inc. Passive Investment

SC 13G/A 1 us28414h1032070824.txt us28414h1032070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Elanco Animal Health Incorporated - (Name of Issuer) Common Stock - (Title of Class of Securities) 28414H103 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appr

Amendment No. 2, dated as of July 3, 2024, to the Credit Agreement, dated as of August 1, 2020, by and among Elanco Animal Health Incorporated, as borrower, Elanco US Inc., as co-borrower, the subsidiary loan parties party thereto, the lenders and issuing banks party thereto from time to time, Goldman Sachs Bank USA, as term facility agent, collateral agent and security trustee, and JPMorgan Chase Bank, N.A., as revolving facility agent.

Exhibit 10.1 AMENDMENT NO. 2 TO CREDIT AGREEMENT THIS AMENDMENT NO. 2 TO CREDIT AGREEMENT (this “Agreement”), dated as of July 3, 2024, is entered into among ELANCO ANIMAL HEALTH INCORPORATED, a corporation formed under the laws of Indiana (the “Borrower”), ELANCO US INC., a corporation formed under the laws of Delaware (the “Co-Borrower”, and together with the Borrower, the “Borrowers”), the SUBS

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 3, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 Elanco Animal Healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

Elanco Animal Health Incorporated Amended and Restated Bylaws, effective May 30, 2024.

Exhibit 3.2 ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS Adopted as of May 30, 2024 (Effective May 30, 2024) ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS INDEX Page ARTICLE I The Shareholders 1 SECTION 1.1. Annual Meetings 1 SECTION 1.2. Special Meetings 1 SECTION 1.3. Time, Place, and Conduct of Meetings 4 SECTION 1.4. Notice of Meetings 4 SECTION 1.5. Quorum 4 S

Elanco Animal Health Incorporated Amended and Restated Articles of Incorporation, effective May 30, 2024.

Exhibit 3.1 ELANCO ANIMAL HEALTH INCORPORATED (an Indiana corporation) AMENDED AND RESTATED ARTICLES OF INCORPORATION (As amended and restated May 30, 2024) 1. The name of the Corporation shall be ELANCO ANIMAL HEALTH INCORPORATED. 2. The purposes for which the Corporation is formed are to engage in any lawful act or activity for which a corporation may be organized under the Indiana Business Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation) 001-38661 (Commission file number) 2500 Innovation Way, Greenfield Indiana (Address of principal executive offices) 46140 (Zip code) Shiv O’Neill

Elanco Animal Health Reports First Quarter 2024 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2024 Results •First Quarter 2024 Financial Results ◦Revenue of $1,205 million ◦Reported Net income of $32 million, Adjusted Net income of $167 million ◦Adjusted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (I.R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat

Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors New Directors Join the Board’s Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora

Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Joele Frank: Kelly Sullivan / Adam Pollack (212) 355-4449 Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Walla

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 29, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

Cooperation Agreement, dated as of March 29, 2024, by and among Elanco Animal Health Incorporated, Ancora Catalyst Institutional, LP and the other person and entities listed thereto.

Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of March 29, 2024, is made by and among Elanco Animal Health Incorporated, an Indiana corporation (the “Corporation”), and the entities and natural persons set forth under the “Ancora Parties” caption in the signature pages hereto and their Affiliates or Associates (as such terms are defined below) (collecti

LETTER

United States securities and exchange commission logo March 12, 2024 Sebastian Alsheimer Partner, Wilson Sonsini Goodrich & Rosati Elanco Animal Health Inc 1301 Avenue of the Americas 40th Floor New York, NY 10019 Re: Elanco Animal Health Inc Soliciting Materials filed pursuant to Rule 14a-12 by Ancora Holdings Group, LLC et al.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

EX-1

Exhibit 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

February 26, 2024

Exhibit 18 February 26, 2024 Board of Directors Elanco Animal Health, Inc. 2500 Innovation Way Greenfield, IN 46140 Ladies and Gentlemen: Note 2 of the Notes to the consolidated financial statements of Elanco Animal Health, Inc., included in its Annual Report on Form 10-K for the year ended December 31, 2023, describes a change in the method of accounting for inventory valuation from the weighted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Elanco Animal H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-38661 Elan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employ

Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results •Fourth Quarter 2023 Financial Results: ◦Revenue of $1,035 million ◦Reported Net Loss of $141 million, Adjusted Net Income of $39 mi

ELANCO ANIMAL HEALTH INCORPORATED REQUIRED COMPENSATION RECOVERY POLICY Adopted August 15, 2023

Exhibit 97 ELANCO ANIMAL HEALTH INCORPORATED REQUIRED COMPENSATION RECOVERY POLICY Adopted August 15, 2023 Policy The Board of Directors (the “Board”) of ELANCO ANIMAL HEALTH INCORPORATED (the “Company”) has adopted this Required Compensation Recovery Policy (this “Policy”) pursuant to Rule 10D-1 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), the Securities and Exchange Commission (“SEC”) regulations promulgated thereunder, and applicable New York Stock Exchange (“NYSE”) listing standards.

SUBSIDIARIES OF THE COMPANY

SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2023, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Dista Products Limited United Kingdom EIO Insurance Company, Inc. Tennessee (United States) Elanco (Shanghai) Animal Health Co., Ltd. China

ELAN / Elanco Animal Health Incorporated / DODGE & COX - SC 13G/A Passive Investment

SC 13G/A 1 d759338dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3 )* Elanco Animal Health Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat

ELAN / Elanco Animal Health Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0821-elancoanimalhealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Elanco Animal Health Inc Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

ELAN / Elanco Animal Health Incorporated / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment

SC 13G/A 1 elana621224.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Elanco Animal Health Inc (Name of Issuer) COM (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate bo

Asset Purchase Agreement by and between Elanco Animal Health Incorporated as Seller and Intervet International as Buyer dated as of February 5, 2024.*

  Exhibit 2.1   EXECUTION VERSION     ASSET PURCHASE AGREEMENT   BY AND BETWEEN   ELANCO ANIMAL HEALTH, INC.,   as Seller   and   INTERVET INTERNATIONAL B.V.,   as Buyer   DATED AS OF FEBRUARY 5, 2024           Table of Contents     Page     Article I Definitions 1 Section 1.01 Certain Defined Terms 1       Article II Purchase and Sale; Closing 1 Section 2.01 Purchase and Sale of Transferred Asset

Elanco Announces Sale of Aqua Business for $1.3 Billion Transaction reinforces Elanco’s commitment to most significant value creation opportunities in pet health and livestock sustainability Enables company to accelerate debt paydown by $1.05B to $1.

Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Elanco Announces Sale of Aqua Business for $1.3 Billion Transaction reinforces Elanco’s commitment to most significant value creation opportunities in pet health a

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

ELAN / Elanco Animal Health Incorporated / BlackRock Inc. Passive Investment

us28414h1032012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Elanco Animal Health Incorporated - (Name of Issuer) Common Stock - (Title of Class of Securities) 28414H103 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

© 2024 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation

Exhibit 99.1 J.P. Morgan Healthcare Conference January 9, 2024 Jeff Simmons President & Chief Executive Officer © 2024 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation, our long-term revenue and earnings g

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Elanco Animal He

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

Elanco Animal Health Announces Planned Board Leadership Changes and Corporate Governance Actions Lawrence Kurzius to become next Chairman of the Board

Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Elanco Animal Health Announces Planned Board Leadership Changes and Corporate Governance Actions Lawrence Kurzius to become next Chairman of

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

ELAN / Elanco Animal Health Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment

SC 13G/A 1 elana5110823.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Elanco Animal Health Inc (Name of Issuer) COM (Title of Class of Securities) 28414H103 (CUSIP Number) October 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate bo

Elanco Animal Health Reports Third Quarter 2023 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2023 Results •Third Quarter 2023 Financial Results ◦Revenue of $1,068 million, representing 4% reported growth or 5% excluding the impact of foreign exchange ra

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Hea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 Elanco Animal He

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

Elanco Announces Corporate Governance Enhancements

Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Elanco Announces Corporate Governance Enhancements GREENFIELD, Ind. (October 4, 2023) – Elanco Animal Health Incorporated (NYSE: ELAN) announ

ELAN / Elanco Animal Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Elanco Animal Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: August 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is file

Receivables Loan Agreement among Elanco SPEAR LLC, Elanco US Inc., The Various Lenders and Lender Agents from Time to Time Party Thereto and Coöperatieve Rabobank U.A., New York Branch, dated as of August 3, 2023 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on August 7, 2023).

Exhibit 10.1 EXECUTION COPY RECEIVABLES LOAN AGREEMENT among ELANCO SPEAR LLC, as Borrower ELANCO US INC., as initial Servicer THE VARIOUS LENDERS AND LENDER AGENTS FROM TIME TO TIME PARTY HERETO and COÖPERATIEVE RABOBANK U.A., NEW YORK BRANCH, as Administrative Agent Dated as of August 3, 2023 Table of Contents Page ARTICLE I AMOUNTS AND TERMS OF THE ADVANCES 1 Section 1.1. Advances and Making Lo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health I

Elanco Animal Health Reports Second Quarter 2023 Results and Raises Full Year Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2023 Results and Raises Full Year Guidance · Second Quarter 2023 Financial Results ◦ Revenue of $1,057 million, impacted by an estimated $90-$110 million of re

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

Environmental Protection Agency (EPA) Completes Review of Seresto® Collar and Confirms Continued Registration; Data Affirms Safety Profile of the Product

Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact: Season Solorio (765) 316-0233 [email protected] Investor Contact: Kathryn Grissom (317) 273-9284 [email protected] Environmental Protection Agency (EPA) Completes Review of Seresto® Collar and Confirms Continued Registration; Data Affirms Safety Profile of the Product · Comprehensive, multi-year review by the EPA, with support

Exhibit 99.2 Seresto® Stewardship Program On July 13, 2023, Elanco Animal Health Incorporated and the Environmental Protection Agency (EPA) announced that the EPA, with support from the Food and Drug Administration (FDA), completed its comprehensive,

Exhibit 99.2 Seresto® Stewardship Program On July 13, 2023, Elanco Animal Health Incorporated and the Environmental Protection Agency (EPA) announced that the EPA, with support from the Food and Drug Administration (FDA), completed its comprehensive, multi-year review of the Seresto® flea and tick collar. EPA confirms continued registration of the collar. Comprehensive data affirms the safety prof

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Elanco Animal Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 Elanco Animal Healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

ELAN / Elanco Animal Health Inc / BlackRock Inc. Passive Investment

us28414h1032060623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) Elanco Animal Health Incorporated - (Name of Issuer) Common Stock - (Title of Class of Securities) 28414H103 - (CUSIP Number) May 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation) 001-38661 (Commission file number) 2500 Innovation Way, Greenfield Indiana (Address of principal executive offices) 46140 (Zip code) Marcela A. Ki

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2023 Elanco Animal Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Comm

As filed with the Securities and Exchange Commission on May 19, 2023

As filed with the Securities and Exchange Commission on May 19, 2023 Registration Statement No.

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Elanco Animal Health Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, no par value 457(c) and 457(h) 5,375,000 (2) $ 8.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Elanco Animal Health

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commi

Elanco Animal Health Reports First Quarter 2023 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2023 Results · First Quarter 2023 Financial Results ◦ Revenue of $1,257 million, including an estimated $90-$110 million benefit from customer purchasing shifte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Elanco Animal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation

SUBSIDIARIES OF THE COMPANY

SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2022, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Aratana Therapeutics, Inc. Delaware (United States) ChemGen Corporation Massachusetts (United States) Dista Products Limited United Kingdom

The Elanco Corporate Bonus Plan (as amended effective January 1, 2023) TABLE OF CONTENTS

EXHIBIT 10.23 The Elanco Corporate Bonus Plan (as amended effective January 1, 2023) TABLE OF CONTENTS SECTION 1. PURPOSE 1 SECTION 2. DEFINITIONS 1 SECTION 3. ADMINISTRATION 6 SECTION 4. PARTICIPATION IN THE PLAN 7 SECTION 5. DEFINITION AND COMPUTATION OF COMPANY BONUS 8 SECTION 6. TIME OF PAYMENT 11 SECTION 7. ADMINISTRATIVE GUIDELINES 12 SECTION 8. MISCELLANEOUS 12 SECTION 9. AMENDMENT, SUSPENS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number 001-38661 Elan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employ

Elanco Animal Health Incorporated Performance-Based Award Agreement

EXHIBIT 10.26 Elanco Animal Health Incorporated Performance-Based Award Agreement This Performance-Based Award is granted on , 2022 (“Grant Date”), by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Performance-Based Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at http://equity.elanco

Exhibit 4.5

EXHIBIT 4.5 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Elanco Animal Health Incorporated (“Elanco”) has one class of securities, its common stock, no par value, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Description of common stock The following is a summary of Elanco

Elanco Animal Health Incorporated Consolidated Statements of Operations (Dollars and shares in millions, except per share data)

Exhibit 99.1 The financial tables in this Exhibit 99.1 reflect the revisions to previously reported financial results related to the identified immaterial errors as noted in the Form 8-K/A filed March 1, 2023 (the "Form 8-K/A"). Revised Financial Highlights The table below includes the following pet health revenue revisions: fourth quarter of 2022 was decreased by $3 million and fourth quarter of

EXHIBIT 10.27 Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement This Nonqualified Stock Option is granted on _______ __, 2022 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation, (“Elanco” or the “Com

ex1027elanconon-qualifie EXHIBIT 10.27 Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement This Nonqualified Stock Option is granted on , 2022 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation, (“Elanco” or the “Company”), to the Eligible Individual who has received this Nonqualified Stock Option Award Agreement (the “Grantee”). Number of Shares: L

EXHIBIT 10.25 Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on __________ __, 2022 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Com

ex1025elanco-onxcyclersu EXHIBIT 10.25 Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2022 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”). Number of Shares: Log into

Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results • Fourth Quarter 2022 Financial Results: ◦ Revenue of $988 million ◦ Reported Net Loss of $54 million, Adjusted Net Income of $95 mi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Elanco Animal H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

ELAN / Elanco Animal Health Inc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 elan13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) ELANCO ANIMAL HEALTH INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 28414H103 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rul

ELAN / Elanco Animal Health Inc / DODGE & COX - SC 13G/A Passive Investment

SC 13G/A 1 d465178dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate

ELAN / Elanco Animal Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Elanco Animal Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

ELAN / Elanco Animal Health Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment

SC 13G/A 1 elana420923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Elanco Animal Health Inc (Name of Issuer) COM (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate bo

ELAN / Elanco Animal Health Inc / BlackRock Inc. Passive Investment

SC 13G/A 1 us28414h1032013123.txt us28414h1032013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Elanco Animal Health Incorporated - (Name of Issuer) Common Stock - (Title of Class of Securities) 28414H103 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on February 13, 2023, pursuant to the provisions of Rule 12d2-2 (a).

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 31, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

© 2023 Elanco or its affiliates This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitat

EX-99.1 2 tm232554d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 J.P. Morgan Healthcare Conference January 10, 2023 Jeff Simmons President & Chief Executive Officer © 2023 Elanco or its affiliates This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

TRADING DATA

EX-99.7 2 sa58394498-ex997.htm TRADING DATA EXHIBIT 99.7 TRADING DATA The following table sets forth all transactions in the Common Stock of the Issuer effected in the last sixty days by the Sachem Head Funds. Name Trade Date Buy/ Sell No. of Shares/ Quantity Unit Cost/ Proceeds Security Sachem Head LP 11/01/2022 Buy 6,600 13.19 Common Stock* Sachem Head LP 12/01/2022 Sell 7,700 12.87 Common Stock

ELAN / Elanco Animal Health Inc / Sachem Head Capital Management LP - AMENDMENT NO. 4 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 28

ELAN / Elanco Animal Health Inc / DODGE & COX - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

ELAN / Elanco Animal Health Inc / Aristotle Capital Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 28414H103 (CUSIP Number) Michelle Gosom Arist

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health In

Elanco Animal Health Reports Third Quarter 2022 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2022 Results ? Third Quarter 2022 Financial Results ? Revenue of $1,028 million ? Reported Net Loss of $49 million, Adjusted Net Income of $96 million ? Adjuste

ELAN / Elanco Animal Health Inc / Sachem Head Capital Management LP - SCHEDULE 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 28

TRADING DATA

EXHIBIT 99.5 TRADING DATA The following table sets forth all transactions in the Common Stock of the Issuer effected in the last sixty days by the Sachem Head Funds. Name Trade Date Buy/ Sell No. of Shares/ Quantity Unit Cost/ Proceeds Security SH Stony Creek Master Ltd. 9/8/22 Buy 800,000 $14.4649 Common Stock

Scott D. Ferguson 250 West 55th Street, 34th Floor New York, NY 10019

EXHIBIT 99.6 Scott D. Ferguson 250 West 55th Street, 34th Floor New York, NY 10019 September 7, 2022 Board of Directors Elanco Animal Health Incorporated 2500 Innovation Way Greenfield, IN 46140 Attention: Chairman of the Board of Directors Re: Resignation Ladies and Gentlemen: I hereby resign from my position as a director of Elanco Animal Health Incorporated (the ?Company?) and from any and all

Elanco Announces Changes to its Board of Directors Scott Ferguson steps down from the Board Sachem Head expresses confidence in Elanco’s leadership and strategy

Exhibit 99.1 Elanco Announces Changes to its Board of Directors Scott Ferguson steps down from the Board Sachem Head expresses confidence in Elanco?s leadership and strategy GREENFIELD, Ind. ? September 8, 2022 ? Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Scott Ferguson, founder and managing partner of Sachem Head Capital Management LP (?Sachem Head?), has stepped down fro

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 ☐ Transition Report Pursuant To Section

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as

Consulting Agreement, dated April 12, 2022, by and between Aaron Schacht and Elanco US Inc. (filed herewith).

Exhibit 10.1 Consulting Agreement This CONSULTING AGREEMENT (the ?Agreement?) is made by and between Aaron Schacht (?you? or ?Consultant?) and Elanco US Inc., and its affiliates (the ?Company?) (collectively, the ?Parties?). RECITALS WHEREAS, the Company desires that Consultant provide certain Services (as defined below) to the Company and its affiliates; and WHEREAS, Consultant desires to perform

Amended and Restated Articles of Incorporation of Elanco Animal Health Incorporated, effective May 18, 2022 (

Exhibit 3.1 ELANCO ANIMAL HEALTH INCORPORATED (an Indiana corporation) AMENDED AND RESTATED ARTICLES OF INCORPORATION (As amended and restated May 20, 2022) 1. The name of the Corporation shall be ELANCO ANIMAL HEALTH INCORPORATED. 2. The purposes for which the Corporation is formed are to engage in any lawful act or activity for which a corporation may be organized under the Indiana Business Corp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Co

Elanco Animal Health Reports Second Quarter 2022 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2022 Results ? Second Quarter 2022 Financial Results ? Revenue of $1,177 million ? Reported Net Loss of $22 million, Adjusted Net Income of $177 million ? Adju

ELAN / Elanco Animal Health Inc / DODGE & COX - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

Incremental Assumption Agreement dated June 28, 2022 by and among Elanco Animal Health Incorporated, Elanco US Inc., the subsidiary loan parties party thereto, Bank of America, N.A., as incremental term lender, each other person party thereto as incremental term lender, and Goldman Sachs Bank USA, as the term facility agent.

? Exhibit 10.1 ? Execution Version ? INCREMENTAL ASSUMPTION AGREEMENT ? THIS INCREMENTAL ASSUMPTION AGREEMENT (this ?Agreement?) dated and effective as of June?28, 2022 (the ?Effective Date?), is among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the ?Company?), ELANCO US INC., a Delaware corporation (together with the Company, collectively, the ?Borrowers? and each, individually, a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation) 001-38661 (Commission file number) 2500 Innovation Way, Greenfield Indiana (Address of principal executive offices) 46140 (Zip code) Marcela A. Ki

As filed with the Securities and Exchange Commission on May 19, 2022

As filed with the Securities and Exchange Commission on May 19, 2022 Registration Statement No.

Elanco Animal Health Incorporated Amended and Restated Employee Stock Purchase Plan.

Exhibit 10.1 ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN The purpose of the Elanco Animal Health Incorporated Employee Stock Purchase Plan, as it may be amended from time to time (the ?Plan?), is to assist employees of Elanco Animal Health Incorporated, an Indiana corporation, and any successor corpora

Amended and Restated Bylaws of Elanco Animal Health Incorporated, effective May 18, 2022 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the Commission on May 19, 2022).

Exhibit 3.1 ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS Adopted as of February 22, 2022 (Effective May 18, 2022) ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS INDEX Page Article I The Shareholders 1 Section 1.1. Annual Meetings 1 Section 1.2. Special Meetings 1 Section 1.3. Time, Place, and Conduct of Meetings 1 Section 1.4. Notice of Meetings 1 Section 1.5. Quoru

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Comm

Filing Fee Table.

Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Elanco Animal Health Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, no par value 457(c) and 457(h) 625,000 (1) $ 22.

Elanco Animal Health Reports First Quarter 2022 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2022 Results ? First Quarter 2022 Financial Results ? Revenue of $1,225 million ? Reported Net Income of $48 million, Adjusted Net Income of $177 million ? Adju

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ☐ Transition Report Pursuant To Section 13 or 15(d)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 19, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

Incremental Assumption Agreement dated April 19, 2022 by and among Elanco Animal Health Incorporated, Elanco US Inc., the subsidiary loan parties party thereto, Farm Credit Mid-America, PCA, as incremental term lender, and Goldman Sachs Bank USA, as the term facility agent.

Exhibit 10.1 EXECUTION VERSION INCREMENTAL ASSUMPTION AGREEMENT THIS INCREMENTAL ASSUMPTION AGREEMENT (this ?Agreement?) dated and effective as of April 19, 2022 (the ?Effective Date?), is among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the ?Company?), ELANCO US INC., a Delaware corporation (together with the Company, collectively, the ?Borrowers? and each, individually, a ?Borrow

Elanco Animal Health Incorporated Announces Early Results of Tender Offer and Increase in Tender Cap for 2023 Notes

Exhibit 99.2 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Incorporated Announces Early Results of Tender Offer and Increase in Tender Cap for 2023 Notes Greenfield, IN, (April 12, 2022) (BUSINESSWIRE) - Elanco Animal Health Incorporated (NY

Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein product

Exhibit 99.1 Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein production, and livestock disease monitoring GREENFIELD, IN and BOSTON, MA (April 11, 2022) ? Elanco Animal Health Incorporated (NYSE: ELAN), a

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 11, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 ny20002367x3def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission On

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes Greenfield, IN, (March 29, 2022) (BUSINESSWIRE) - Elanco Animal Health Incorporated (NYSE: ELAN) (?Elanco?) today announced the com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Commission file number 001-38661 Elanco Anima

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employer incor

Services Agreement, dated as of January 1, 2022, by and between MBRD Service Company and Elanco US Inc. (incorporated by reference to Exhibit 10.17 of the Annual Report on Form 10-K filed with the SEC on February 28, 2022).

Exhibit 10.17 SERVICES AGREEMENT This Services Agreement (this ?Agreement?), dated as of January 1, 2022 (the ?Effective Date?), is by and between MBRD Service Company, an Indiana limited liability company, with offices located at 9400 Priority Way W. Drive, Indianapolis, IN 46240 (the ?Service Provider?) and Elanco US Inc., a Delaware corporation, with offices located at 2500 Innovation Way, Gree

SUBSIDIARIES OF THE COMPANY

SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2021, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Aratana Therapeutics, Inc. United States ChemGen Corporation Massachusetts Dista Products Limited United Kingdom Elanco (Shanghai) Animal He

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

Elanco Animal Health Reports Fourth Quarter and Full Year 2021 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2021 Results ? Full year 2021 revenue was $4,765 million, an increase of 46 percent, including $1,311 million of incremental revenue from Bayer A

Elanco Animal Health Incorporated Amended and Restated Bylaws, effective February 22, 2022.

Exhibit 3.1 ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS Adopted as of February 22, 2022 (Effective February 22, 2022) ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS INDEX Page Article I The Shareholders 1 Section 1.1. Annual Meetings 1 Section 1.2. Special Meetings 1 Section 1.3. Time, Place, and Conduct of Meetings 1 Section 1.4. Notice of Meetings 1 Section 1.5.

ELAN / Elanco Animal Health Inc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) Elanco Animal Health Inc (Name of Issuer) COMMON STOCK (Title of Class of Securities) 28414H103 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sche

ELAN / Elanco Animal Health Inc / Aristotle Capital Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 28414H103 (CUSIP Number) Michelle Gosom Arist

ELAN / Elanco Animal Health Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Elanco Animal Health Inc (Name of Issuer) COM (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

ELAN / Elanco Animal Health Inc / JANUS HENDERSON GROUP PLC - JANUS HENDERSON GROUP PLC OWNS <5% Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: Elanco Animal Health Incorporated Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: 12/31/2021 Check the appropriate box to designate the rule pursuant to which this S

ELAN / Elanco Animal Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Elanco Animal Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

ELAN / Elanco Animal Health Inc / BlackRock Inc. Passive Investment

us28414h1032020822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Elanco Animal Health Incorporated - (Name of Issuer) Common Stock - (Title of Class of Securities) 28414H103 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

January 11, 2022 J.P. Morgan Healthcare Conference Jeff Simmons President & Chief Executive Officer

Exhibit 99.1 January 11, 2022 J.P. Morgan Healthcare Conference Jeff Simmons President & Chief Executive Officer This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation , our long - term revenue and earnings growth expectations, reduc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 1, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction (Commission (I.R.S.

Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and Innovation Opportunities

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Dave Pugh (317) 361-9892 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and Innovation Opportunities ? Streamlining and simplifying organizational structure to reduce

Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 29, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ Transition Report Pursuant To Section 13 or 15

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specifie

Elanco Animal Health Reports Third Quarter 2021 Results Exceeding Revenue Guidance; Raising Full Year 2021 Revenue Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Dave Pugh (317) 361-9892 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2021 Results Exceeding Revenue Guidance; Raising Full Year 2021 Revenue Guidance ? Third quarter revenue increased 27 percent, benefiting from increased scale and diversif

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 5, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

1

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (302) 897-0668 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Announces New Innovation Leader, Additional Strategic Move to Increase Focus on High-Value, Late-Stage Pet Health Pipeline Progress ? Ellen de Brabander, Ph.D., joins Elanco to lead Innovation and R

ELAN / Elanco Animal Health Inc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Elanco Animal Health Inc (Name of Issuer) COMMON STOCK (Title of Class of Securities) 28414H103 (CUSIP NUMBER) August 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedu

KIN / Kindred Biosciences Inc / Elanco Animal Health Inc - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Kindred Biosciences, Inc. (Name of Subject Company — Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 494577109 (CUSIP Number of Class of Securities) Marcela A. Kirberger General Counsel and Corporate Secretary Elanco Ani

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 27, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

Elanco Closes Acquisition of Kindred Biosciences Differentiated, Disruptive Portfolio Positions Elanco for Next Era of Pet Health Growth

Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga, 302-897-0668, [email protected] Media Contact: Colleen Parr Dekker, 317-989-7011, [email protected] Elanco Closes Acquisition of Kindred Biosciences Differentiated, Disruptive Portfolio Positions Elanco for Next Era of Pet Health Growth GREENFIELD,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C

Incremental Assumption Agreement dated August 12, 2021 by and among Elanco Animal Health Incorporated, Elanco US Inc., the subsidiary loan parties party thereto, Farm Credit Mid-America, PCA, as incremental term lender and Goldman Sachs Bank USA, as the term facility agent

Exhibit 10.1 Execution Version INCREMENTAL ASSUMPTION AGREEMENT THIS INCREMENTAL ASSUMPTION AGREEMENT (this ?Agreement?) dated and effective as of August 12, 2021 (the ?Effective Date?), is among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the ?Company?), ELANCO US INC., a Delaware corporation (together with the Company, collectively, the ?Borrowers? and each, individually, a ?Borro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Elanco Animal Health Reports Second Quarter 2021 Results Exceeded second quarter 2021 guidance; Increasing full year 2021 revenue outlook

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (302) 897-0668 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2021 Results Exceeded second quarter 2021 guidance; Increasing full year 2021 revenue outlook ? Revenue in the second quarter was $1,279 million, comprised of $7

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Co

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 ☐ Transition Report Pursuant To Section 13 or 15(d) o

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in

Press Release issued by Elanco Animal Health Incorporated, August 9, 2021.

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (302) 897-0668 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2021 Results Exceeded second quarter 2021 guidance; Increasing full year 2021 revenue outlook ? Revenue in the second quarter was $1,279 million, comprised of $7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration Statement No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 30, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 Elanco Animal Healt

DFAN14A 1 tm2118507d8dfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com

First Amendment to Agreement and Plan of Merger, dated as of June 30, 2021, by and among Elanco Animal Health Incorporated, Knight Merger Sub, Inc. and Kindred Biosciences, Inc.

Exhibit 2.1 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER This First Amendment (this ?Amendment?) is made and entered into as of June 30, 2021, by and among Elanco Animal Health Incorporated, an Indiana corporation (?Parent?), Knight Merger Sub, Inc., a Delaware corporation and direct wholly-owned subsidiary of Parent (?Merger Sub?), and Kindred Biosciences, Inc., a Delaware corporation (the ?Co

Exhibit 2.1 to Elanco’s Current Report on Form 8-K filed with the SEC on July 1, 2021

Exhibit 2.1 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER This First Amendment (this ?Amendment?) is made and entered into as of June 30, 2021, by and among Elanco Animal Health Incorporated, an Indiana corporation (?Parent?), Knight Merger Sub, Inc., a Delaware corporation and direct wholly-owned subsidiary of Parent (?Merger Sub?), and Kindred Biosciences, Inc., a Delaware corporation (the ?Co

Exclusivity Agreement, dated as of May 31, 2021, between Elanco Animal Health Incorporated and Kindred Biosciences, Inc.

Exhibit 99.3 STRICTLY PRIVATE & CONFIDENTIAL May 31, 2021 Richard Chin, M.D. Chief Executive Officer Kindred Biosciences, Inc. 1555 Bayshore Highway, Suite #200 Burlingame, CA 94010 Dear Dr. Chin, Reference is made to our discussions regarding the proposed acquisition (the ?Proposed Transaction?) of all of the issued and outstanding equity interests of Kindred Biosciences, Inc. (the ?Company?) by

Mutual Confidentiality Agreement, dated as of January 11, 2020, between Elanco Animal Health Incorporated and Kindred Biosciences, Inc.

Exhibit 99.2 MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (this ?Agreement?) is entered into as of January 11, 2020 by and between Kindred Biosciences, Inc., a Delaware corporation with its principal place of business at 1555 Bayshore Highway, Suite 200, Burlingame, California 94010 USA (?KindredBio?) and Elanco US Inc., a Delaware corporation with its principal place of

Amendment to Exclusivity Agreement, dated as of June 11, 2021, between Elanco Animal Health Incorporated and Kindred Biosciences, Inc.

Exhibit 99.4 STRICTLY PRIVATE & CONFIDENTIAL June 11, 2021 Richard Chin, M.D. Chief Executive Officer Kindred Biosciences, Inc. 1555 Bayshore Highway, Suite #200 Burlingame, CA 94010 Dear Dr. Chin, Reference is made to that letter agreement (the ?Letter Agreement?), dated as of May 31, 2021, between Kindred Biosciences, Inc. (the ?Company?) and Elanco Animal Health Incorporated (?Elanco?). In acco

Joint Filing Agreement, dated as of June 25, 2021, between Elanco Animal Health Incorporated and Knight Merger Sub, Inc.

Exhibit 99.5 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Kindred Biosciences, Inc., a Delaware corporation, and further agree

KIN / Kindred Biosciences Inc / Elanco Animal Health Inc - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 Kindred Biosciences, Inc. (Name of Subject Company — Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 494577109 (CUSIP Number of Class of Securities) Marcela A. Kirberger General Counsel and Corporate Secretary Elanco Animal Health Incorpora